In lung cancer, NGS has demonstrated that missense mutations and abrogating mutations occur far more infrequently (< 5%) than the frequency of BRG1 loss (by immunohistochemistry (IHC):15-30%) [24–28]. This evidence concerns the gene SMARCA4 and lung carcinoma.